文献速递认知障碍与痴呆

血浆磷酸化tau217与无认知障碍老年人淀粉样蛋白负荷的荟萃分析

Plasma Phosphorylated Tau 217 and Amyloid Burden in Older Adults Without Cognitive Impairment: A Meta-Analysis.
PubMed 文献 · JAMA Neurol · 2026-01-01

该荟萃分析纳入18项研究共7834名无认知障碍老年人,评估血浆p-tau217区分淀粉样蛋白阳性与阴性的效应量和诊断准确性。结果显示p-tau217效应量大(Hedges g=1.50),汇总AUC为0.87,提示其可作为临床前阿尔茨海默病的可靠筛查工具。

要点

  • 血浆p-tau217在无认知障碍老年人中区分淀粉样蛋白阳性的汇总AUC为0.87。
  • 淀粉样蛋白阳性与阴性组间p-tau217均值差异效应量大(Hedges g=1.50)。
  • p-tau217有助在临床前阶段识别阿尔茨海默病病理,支持早期干预。

核心结论

  • 血浆p-tau217能可靠检测临床前阶段阿尔茨海默病病理,可作为可扩展、微创的早期识别工具。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase和EBSCOhost数据库自建库至2025年9月1日。
  • 纳入报告无认知障碍老年人淀粉样蛋白阳性与阴性组p-tau217数值数据的观察性研究或随机临床试验。
  • 共分析18篇文献、7834名参与者(淀粉样蛋白阳性2533例,阴性5301例)。

主要发现

  • p-tau217的标准化均数差异效应量大(Hedges g=1.50;95% CI,1.33-1.68)。
  • p-tau217识别无认知障碍淀粉样蛋白阳性个体的汇总AUC为0.87(95% CI,0.85-0.90)。

临床怎么用

  • 可将血浆p-tau217作为无认知障碍老年人临床前阿尔茨海默病病理的微创筛查工具。
  • 在可及时启动疾病修饰治疗的场景中,p-tau217有助早期识别获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Blood-based biomarkers (BBMs) demonstrate high accuracy in detecting Alzheimer disease (AD) pathological changes in symptomatic individuals. In autosomal dominant AD and in individuals with Down syndrome, both populations with near-universal development of AD pathology, elevations in BBMs are detectable years before clinical onset, supporting their utility for identifying preclinical disease in these cases. Among BBMs, plasma phosphorylated tau 217 (p-tau217) exhibits strong concordance with established in vivo markers of AD pathology. However, its ability to identify older adults without cognitive impairment who are amyloid-positive remains variable across studies and settings. OBJECTIVE: To assess the standardized effect size of mean differences and classification accuracy of p-tau217 for published studies that compared amyloid-positive and amyloid-negative older adults without cognitive impairment. DATA SOURCES: PubMed, Embase, and EBSCOhost databases from inception to September 1, 2025. STUDY SELECTION: Observational studies or randomized clinical trials with baseline data on individuals without cognitive impairment who were classified as either amyloid positive or amyloid negative and reported numeric data for p-tau217 levels. DATA EXTRACTION AND SYNTHESIS: The Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) reporting guideline was used for this study. Two authors independently carried out literature searches to identify studies with older adults without cognitive impairment who were classified as either amyloid positive or amyloid negative where p-tau217 was quantified. MAIN OUTCOME AND MEASURE: The standardized mean difference (Hedges g) was used to characterize differences in mean p-tau217 levels. A pooled area under the curve (AUC) value was used to summarize the diagnostic accuracy of p-tau217 in identifying amyloid-positive individuals. Between-study heterogeneity was investigated using subgroup and sensitivity analyses. Publication bias was assessed using Egger tests. RESULTS: Data for 7834 participants (2533 amyloid positive, 5301 amyloid negative) from 18 publications were analyzed. A large effect size was observed for p-tau217 (Hedges g = 1.50; 95% CI, 1.33-1.68). Values for p-tau217 also demonstrated high accuracy for identifying amyloid-positive individuals without cognitive impairment (AUC = 0.87; 95% CI, 0.85-0.90). CONCLUSION AND RELEVANCE: These findings demonstrate that plasma p-tau217 can reliably detect AD pathology in the preclinical stage. These findings support the clinical utility of plasma p-tau217 as a scalable, minimally invasive tool for early identification of AD, particularly in settings where timely intervention with disease-modifying therapies may offer the greatest benefit in slowing or preventing disease progression.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Malek-Ahmadi M, Sharma S, Stipho F, et al. Plasma Phosphorylated Tau 217 and Amyloid Burden in Older Adults Without Cognitive Impairment: A Meta-Analysis. JAMA Neurol. 2026. PMID: 41324928. doi:10.1001/jamaneurol.2025.4721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。